Literature DB >> 1657002

Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity.

A Habteyesus1, A Nordenskjöld, C Bohman, S Eriksson.   

Abstract

Three key enzymes in the anabolic phosphorylation of deoxyribonucleosides and deoxyribonucleoside analogs were purified i.e. cytoplasmic thymidine kinase (TK1), mitochondrial thymidine kinase (TK2) and cytoplasmic deoxycytidine kinase (dCK) from human, mouse and monkey liver and spleen. Their subunit structure and substrate specificities were compared. Extensive purification of TK1 and dCK from mouse spleen and TK2 from mouse and monkey livers revealed major polypeptide bands of 25, 30 and 28 kD, respectively, on sodium dodecyl sulphate-polyacrylamide gel electrophoresis which are very similar to the subunit molecular weights of the corresponding human enzymes. Affinity purified polyclonal antibodies against human dCK also cross-reacted with 30 kD bands in extracts from both mouse and monkey spleen. Thus, the molecular weights of the subunits of these three enzymes appeared to be very similar in all three species. TK1 and TK2 from these different sources appeared to have similar substrate specificities against several deoxyribonucleoside analogs. However, mouse dCK differed significantly from monkey and human dCK in its capacity to phosphorylate dAdo and 2',3'-dideoxycytidine (ddCyd) with a Vmax approximately 10-fold lower than that of the two latter enzymes. The Km and Vmax values for dCyd and arabinocytosine appeared to be very similar with the enzymes from all three species. The fact that mouse dCK shows low activity with dAdo and ddCyd explains differences reported previously in the metabolism of dAdo and ddCyd in mouse compared to that in human lymphocytes. These results argue against the use of mice as model systems for human deoxynucleoside metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657002     DOI: 10.1016/0006-2952(91)90522-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Cloning and expression of human deoxyguanosine kinase cDNA.

Authors:  M Johansson; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.

Authors:  S Lindemalm; J Liliemark; B S Larsson; F Albertioni
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

Authors:  G M Szczech; P Furman; G R Painter; D W Barry; K Borroto-Esoda; T B Grizzle; M R Blum; J Sommadossi; R Endoh; T Niwa; M Yamamoto; C Moxham
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; S L Smith; M G Davis; S E Dunn; C Botteron; A Cecchi; D Linsey; D Linzey; L Frick; M T Paff; A Goulding; K Biron
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Authors:  V Reichelová; G Juliusson; T Spasokoukotskaja; S Eriksson; J Liliemark
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.

Authors:  A H Cory; I A Shibley; J M Chalovich; J G Cory
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

Review 7.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Cladribine modifies functional properties of microglia.

Authors:  L Ø Jørgensen; K H Hyrlov; M L Elkjaer; A B Weber; A E Pedersen; Å Fex Svenningsen; Z Illes
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

9.  Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.

Authors:  E V Genovesi; L Lamb; I Medina; D Taylor; M Seifer; S Innaimo; R J Colonno; D N Standring; J M Clark
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.